betagenon o304
TRANSCRIPT
![Page 1: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/1.jpg)
1
AMPK activator O304
Peripheral Vascular Disease, Type 2 Diabetes & Cancer
![Page 2: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/2.jpg)
AMP-activated protein kinase
(AMPK)
2
- Master regulator of energy charge at
cellular and organism level
- Validated target in energy balance disorders
- Activated by ATP depletion
![Page 3: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/3.jpg)
Identified in cellular screen designed to
identify compounds which activates AMPK
without reducing cellular ATP
3
O304
![Page 4: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/4.jpg)
4
Mechanism of Action
O304
![Page 5: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/5.jpg)
O304 increases p-T172 AMPK
and the downstream target p-S79 AC
in normal cells
5
AMPK
P
T172
AMPK P
S79
ACC
p-T172 AMPKa
AMPKa
p-S79 ACC
ACC
V.C. 2.5
O304 (µM)
10 5
0,0
1,0
2,0
3,0
4,0
V.C. 2.5 5 10
Arb
. U
nits
p-T172 AMPK
O304 (µM)
0,0
1,0
2,0
3,0
4,0
V.C. 2.5 5 10
Arb
. U
nits
p-S79 ACC
O304 (µM)
![Page 6: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/6.jpg)
O304 activates AMPK and increases
cellular ATP
6
Dose and time dependent
1h
p-T172 AMPK
AMPK
2.5 5 10 V.C.
O304 (µM)
p-T172 AMPK
AMPK
8h
2.5 5 10 V.C.
O304 (µM)
p-172 AMPK
AMPK
16h
2.5 5 10 V.C.
O304 (µM)
ATP/prot
1,0 1,0 1,0 1,1
0,0
0,5
1,0
1,5
2,0
2,5
Arb
. U
nits
V.C. 2.5 5 10
O304 (µM)
ATP/prot
1,0 1,0 1,1 1,3
0,0
0,5
1,0
1,5
2,0
2,5
2.5 5 10
O304 (µM)
V.C.
1,0
1,2 1,4
1,8
0,0
0,5
1,0
1,5
2,0
2,5 ATP/prot
2.5 5 10
O304 (µM)
V.C.
![Page 7: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/7.jpg)
Both O304 and Metformin activates AMPK
7
0,0
1,0
2,0
3,0
4,0
V.C. 2.5 5 10 1 2 5
Re
lative
p-T
17
2 A
MP
K
le
ve
l
p-T172 AMPK/AMPK
Metformin (mM)
O304 (M)
V.C. 2.5 5 10 1 2 5
O304 (M)
AMPK
ACC
p-T172 AMPK
p-S79 ACC
Metformin (mM)
HUVEC
0,0
0,5
1,0
1,5
V.C. 2.5 5 10 1 2 5
Rela
tive A
TP
/pro
tein
levels
ATP/prot
Metformin (mM)
O304 (M)
O304 increases-Metformin decreases
cellular ATP
![Page 8: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/8.jpg)
8
Rate of dephosphorylation of p-T172 AMPK
key regulatory mechanism
- Main upstream kinase LKB1 is constitutively active
- AMP and ADP inhibit dephosphorylation of p-T172 AMPK
- AMP but not ADP allosterically activates AMPK
- Phosphorylation of T172 AMPK is required for activity
- AMPK activated by ATP depletion
![Page 9: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/9.jpg)
Garcia-Haro et. al., 2010
Protein phosphatases PP1 and PP2C
dephosphorylate p-T172 AMPK
9
![Page 10: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/10.jpg)
O304 suppresses the dephosphorylation of
human recombinant p-T172 AMPK
by PP2C (and PP1)
Developed ELISA to monitor the dephosphorylation of p-T172 AMPK
10
AMPK111
0,0
0,2
0,4
0,6
0,8
1,0
1,2
p-T
172 A
MP
K
A
rb.
Units
AMPK
PP2C
0,0
0,2
0,4
0,6
0,8
1,0
1,2
AMPK211
AMPK
PP2C 2.5 5 10
O304 (M)
2.5 5 10
O304 (M)
![Page 11: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/11.jpg)
11
Rat liver AMPK
p-T172 AMPK
PP2C AMPK
10M 150M
O304 ADP
0,0
0,2
0,4
0,6
0,8
1,0
1,2
Rela
tive
p-1
72
AM
PK
a l
eve
l
Human recombinant AMPK
p-T172 AMPK
0,0
0,2
0,4
0,6
0,8
1,0
1,2
Rela
tive
p-1
72
AM
PK
le
ve
l
PP2C AMPK
10M 150M
O304 ADP
O304 suppresses the dephosphorylation of
p-T172 AMPK by PP2C of partially
purified rat liver AMPK
![Page 12: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/12.jpg)
O304 does not inhibit PP2C or PP1
12
0
10000
20000
30000
40000
50000
RFU
PP1
PP1 -PP1 2.5 5 10
O304 (M)
0
10000
20000
30000
40000
50000
RF
U
PP2C
PP2C -PP2C 2.5 5 10
O304 (M)
![Page 13: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/13.jpg)
O304 does not activate AMPK in
LKB1-deficient HeLa cells
AMPK P T172
AMPK LKB1 X
13
ACC
AMPK
p-S79 ACC
p-T172 AMPK
V.C. 2.5 5 10 1
Ionomycin O304(M) (M)
Ca2+ Ionophore
O304 requires LKB1
Activation of AMPK only in physiologically relevant cells!
![Page 14: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/14.jpg)
14
AMPK
P T172
AMPK
P T172
AMPK
P T172
LKB1
PP2C/PP1
AMPK
P T172 O304 X
O304 suppresses the dephosphorylation of p-T172 AMPK
by PP2C and PP1 without inhibiting their activity
Mechanism of action of O304
![Page 15: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/15.jpg)
15
On-target
AMPK activity declines with aging and obesity
Mice fed very high fat diet (vHFD)
Animal model
![Page 16: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/16.jpg)
High oral availability of O304
16
Single dose in rat
0
1000
2000
3000
4000
O304 20mg/kg O304 40mg/kg
Arb
. U
nits
AUC
0
20
40
60
80
100
120
140
0 20 40 60
O304 µ
M
Time (h)
PK
O304 40 mg/kg
O304 20 mg/kg
![Page 17: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/17.jpg)
O304 activates AMPK in liver
of mice fed vHFD
17
**
0
0,5
1
1,5
2
V.C. O304 20mg/kg
Rela
tive
pT
17
2-A
MP
K le
ve
l
p-T172 AMPK / AMPK
V.C. O304 20mg/kg
p-T172 AMPK
AMPK
Mice were treated with O304 at 20mg/kg and fed vHFD for 13 weeks
![Page 18: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/18.jpg)
Chronic AMPK activation
regulates expression of target genes
18
Hardie, et. al., Chemistry&Biology 19, 2012
![Page 19: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/19.jpg)
O304 suppresses the expression of
ACC, FAS, and SCD-1and reduces fatty liver
in mice fed vHFD
19
Mice were fed vHFD for 3 weeks and thereafter O304 at 40mg/kg/day and vHFD for 10 weeks
FASN
SCD-1
-Actin
ACC
V.C. O304 40mg/kg
0
20
40
60
80
100
120
VC O304
To
tal lip
ids (
mg/g
liv
er)
*
0
5
10
15
20
25
30
35
40
VC O304
Trig
lycerd
es (
mg/g
liv
er)
*
![Page 20: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/20.jpg)
AMPK
Vascular system
20
![Page 21: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/21.jpg)
Multiple proposed beneficial effects of
AMPK activation on vasculature
21
Maintains endothelial redox balance
Relaxes blood vessels / reduces hypertension
Suppresses smooth muscle proliferation
Promotes re-endothelization / vascular repair
Reduces cardiac hypertrophy and ischema / reperfusion damage
Suppresses platelet activation
Increases angiogenesis/arteriogenesis and microvascular perfusion
![Page 22: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/22.jpg)
22
AMPK-Endurance-Vascular function
- AICAR increases endurance in normal sedentary mice
- Loss of AMPK in muscle causes severe reduction in
endurance due to reduced capillary density in muscle
- AICAR increases microvascular perfusion in muscle
- Aged normal sedentary mice
- Genetically obese mice
Animal models-Endurance
![Page 23: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/23.jpg)
O304 increases significantly endurance
of normal sedentary 14 month old mice
23
V.C.
O304
V.C.
O304
0
300
600
900
1200
V.C. O304
(m)
Before treatment
*
0
300
600
900
1200
V.C. O304
(m)
After 30 doses
Distribution of mice exhibiting
different running distance
Before treatment
After 30 doses
Mice were treated with O304 at 20 mg/kg/day for 30 days
0
300
600
900
1200
1500
1800
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
(m)
n=14
n=14
0
300
600
900
1200
1500
1800
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
(m)
n=14
n=14
![Page 24: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/24.jpg)
Significantly lower lactate levels
at exhaustion in normal 14 month old mice
treated with O304
24
p=0.013
*
0,0
1,0
2,0
3,0
4,0
5,0
Rest Exhaustion
Lacta
te m
mol/L
V.C. O304
Blood lactate
Mice were treated with O304 at 20 mg/kg/day for 30 days
![Page 25: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/25.jpg)
O304 increases significantly endurance
in Ob/Ob mice
0
100
200
300
400
V.C. O304
Running distance (m
) *
25
Mice were treated with O304 at 20mg/kg/day for 15 days
![Page 26: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/26.jpg)
Increase in endurance induced by O304
in aged mice persists after 1 week but not after
2 weeks of washout
26
Cardiovascular effect?
![Page 27: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/27.jpg)
Laser Doppler Images (LDI) of left hind paw
O304 increases peripheral blood
perfusion in 14 months old mice
27
8 w. old control mice
14 months old mice V.C.
14 months old mice O304 20 mg/kg/day for 25 days
![Page 28: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/28.jpg)
28
Distribution of individual mice
with different perfusion of left hind paw
0
3
6
9
12
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Max p
erf
usio
n A
rb.
units
8w old
O304
V.C.
p=0.0096
n=10
vs p=0.036
n=13
vs
p=0.098
n=16
vs
n=16
n=16
n=16
![Page 29: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/29.jpg)
O304 - Vascular effects
29
Increases expression of Vegf and nNOS
Increases peripheral blood flow
Increases no. of -SMA+ blood vessels in Soleus muscle
Increases cardiac stroke volume
Reduces blood pressure
Increases bleeding time/reduces platelet activation
Reduces ET-1 and TSP-1 levels
![Page 30: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/30.jpg)
Type 2 Diabetes
30
Insulin resistance and β-cell dysfunction
![Page 31: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/31.jpg)
31
AMPK-Type 2 Diabetes
- Ensures normal glucose sensing in β-cells
- Reduces fat and insulin resistance in liver
- Promotes glucose uptake in muscle
![Page 32: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/32.jpg)
32
- Glucose-stimulated insulin secretion is impaired by
AMPKα2 knockout in β-cells
- Promotes trafficking of KATP channels which couple
glucose metabolism to insulin secretion in β-cells
- Facilitates the decrease in insulin secretion in response
to glucose deprivation
AMPK ensures normal glucose sensing in β-cells
O304 stimulates GSIS
![Page 33: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/33.jpg)
33
Perturbed -cell function in Diabetes
Type 2 Diabetics (~70%) have deposits
of islet amyloid polypeptide (IAPP) in -cells
Rodent IAPP is not amyloidogenic;
IAPP amyloidogenesis in diabetes not well studied
Transgenic overexpression of amyloidogenic
human IAPP in mouse β-cells
Animal model
![Page 34: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/34.jpg)
Macroautophagy eliminates aggregated
proteins in mammalian cells
- AMPK induces autophagy by multiple pathways
including suppression of mTOR signaling
- Exercise induces AMPK and autophagy in muscle
and in pancreatic -cells
34
O304 induces autophagy in -cells
![Page 35: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/35.jpg)
35
Induction of insulin resistance by high fat diet
in mice with perturbed β-cell function due to
overexpression of hIAPP in β-cells
Animal model of Type 2 Diabetes
Studies performed in collaboration with
Prof. H. Edlund Umea University
![Page 36: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/36.jpg)
36
O304 - Type 2 Diabetes
O304 ameliorates both insulin resistance and
β-cell dysfunction - hallmarks of type 2 diabetes
![Page 37: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/37.jpg)
37
Increased plasma levels of IGF-1 are
correlated to increased Diabetes mortality
O304 reduces diet-induced increase
in plasma levels of IGF-1
![Page 38: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/38.jpg)
AMPK - Cancer
- Stabilizes p53, p21WAF1,p27CIP1 and causes cell cycle arrest
- Inhibits the synthesis of fatty acids, triglycerides, cholesterol,
glycogen, ribosomal RNA and proteins, and thus cell growth
- Inhibits mTORC1 and translation of many proteins required
for rapid cell growth
- Exhibits 'anti-Warburg' effect - Promotes oxidative metabolism
![Page 39: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/39.jpg)
39
O304 - Tumour cells
- Inhibits mTORC1 signaling
- Suppresses cell growth and induces
cell cycle arrest
- Suppresses lipid synthesis
- Reduces diet-induced hyperinsulinemia
and increased plasma levels of IGF-1
![Page 40: Betagenon o304](https://reader033.vdocument.in/reader033/viewer/2022060112/556b9d76d8b42ada358b5451/html5/thumbnails/40.jpg)
40
Clinical development of O304
In Phase I clinical trials
Future Indications:
Type 2 Diabetes & Vascular complications
Peripheral vascular disease
Cancer